The loading of antigen-derived peptides onto MHC class I molecules for presentation to cytotoxic T cells is a key process in adaptive immune defense. Loading of MHC I is achieved by a sophisticated machinery, the peptide-loading complex (PLC), which is organized around the transporter associated with antigen processing (TAP) with the help of several auxiliary proteins. As an essential adapter protein recruiting MHC I molecules to TAP, tapasin catalyzes peptide loading of MHC I. However, the exact stoichiometry and basic molecular architecture of TAP and tapasin within the PLC remains elusive. Here, we demonstrate that two tapasin molecules are assembled in the PLC, with one tapasin bound to each TAP subunit. However, one tapasin molecule bound either to TAP1 or TAP2 is sufficient for efficient MHC I antigen presentation. By specific blocking the interaction between tapasin-MHC I complexes and the translocation complex TAP, the MHC I surface expression is impaired to the same extent as with soluble tapasin. Thus, the proximity of the peptide supplier TAP to the acceptor MHC I is crucial for antigen processing. In summary, the human PLC consists maximally of 2؋ tapasin-ERp57/MHC I per TAP complex, but one tapasin-ERp57/MHC I in the PLC is essential and sufficient for antigen processing.-Hulpke, S., Baldauf, C., Tampé, R. Molecular architecture of the MHC I peptide-loading complex: one tapasin molecule is essential and sufficient for antigen processing. FASEB J. 26, 000 -000 (2012). www.fasebj.org
In the fight against microbial and viral invaders, as well as malignant transformation, jawed vertebrates have evolved the sophisticated self-defense system of adaptive immunity. The presentation of mainly proteasomal degradation products on MHC I molecules at the cell surface is a way to carry information about the cellular proteome to cytotoxic T lymphocytes (1) (2) (3) . Efficient antigen processing via MHC I relies on the peptide-loading complex (PLC), consisting of the heterodimeric transporter associated with antigen processing (TAP) as centerpiece, which recruits the peptidereceptive major histocompatibility complex class I (MHC I) heavy-chain/␤ 2 -microglobulin dimer by the adapter protein tapasin (Tsn). The transient Tsn-MHC I interaction is stabilized by the oxidoreductase ERp57, which forms a stable, mixed disulfide conjugate with Tsn (4, 5) , and the endoplasmic reticulum (ER) chaperone calreticulin (CRT), which recognizes the monoglucose unit of N-core glycosylated MHC I molecules. The type I membrane protein Tsn fulfills various functions within the PLC. Its ER-lumenal domain binds to MHC I and its transmembrane domain to a specific interaction scaffold in TAP1 and TAP2, called TMD 0 , thereby connecting the peptide supplier TAP and the peptide acceptor MHC I (6 -10) . Tsn functions as peptide editor/facilitator, promoting the binding of immunodominant peptides (11, 12) . According to current models, peptide exchange is accelerated by Tsn and low-affinity peptides dissociate faster (13) (14) (15) . However, this explanation may be incomplete. The peptide affinity to MHC I does not always correlate with the stability of peptide-MHC I complexes (16, 17) . Since different HLA alleles are known to exhibit different Tsn dependence, the relative effect of Tsn on peptide editing and loading might differ.
Soluble Tsn lacking the transmembrane helix and the cytosolic tail transiently interacts with MHC I but is unable to associate with TAP, and was shown to promote MHC I surface expression in Tsn-deficient human cells to some extent (18 -22) . Tsn also stabilizes the TAP complex (18, 23, 24) . Despite substantial similarities between the MHC I antigen processing pathway in rodents and humans, the relative contributions of the different functions vary considerably. For example, Tsn increases TAP expression 300-fold in mice (23) , but only up to 3-fold in human cells (18) . For human Tsn, mutation of a conserved lysine 408 in the transmembrane helix disrupts the Tsn-TAP interaction (25) . However, the same mutation in mouse Tsn did not affect the interaction with or stabilization of TAP (9, 26) . Only a combination of additional residues flanking the same side of the Tsn transmembrane helix are able to destabilize TAP (9) . Hence, the human Tsn-TAP interaction appears to be more delicate than the mouse equivalent, but mouse TAP seems to be more dependent on the presence of Tsn for its stability.
Despite intensive research, the stoichiometry of the PLC remains to be solved. The number of Tsn molecules per TAP dimer found varies from 1 to 4 (7, 27, 28) . We recently demonstrated that the N-terminal domain (TMD 0 ) comprising a 4-transmembrane helix bundle at each TAP subunit constitutes an autonomous interaction scaffold for the binding of 1 Tsn molecule (10) . However, this does not necessarily mean that indeed 2 Tsn molecules bind simultaneously to TAP and that both are equally required for peptide loading.
Keeping in mind the pronounced differences between MHC I loading in humans and rodents, it is difficult to assemble the data obtained so far into a unifying model, especially since they result from studies using different species. Here, we provide direct evidence that the human PLC harbors 2 Tsn molecules. However, PLCs with a fixed TAP to Tsn stoichiometry of 1:1 are fully capable of mediating MHC I peptide loading. Thus, a single Tsn molecule bound either to TAP1 or TAP2 is essential and sufficient for efficient MHC I loading and surface expression. Moreover, Tsn fused to the TMD 0 s of either TAP1 or TAP2, which cannot interact with the TAP complex, supports MHC I surface presentation only to the same extent as soluble Tsn, suggesting the importance of spatial proximity between TAP and MHC I.
MATERIALS AND METHODS

Cloning and constructs
For the Tsn-TAP fusion constructs, TAP1 was amplified for the primers 5=-TAGGATCCATGGCAAGTTCCAGATGTCCT-GCTCCCA-3= and 5=-TATGATCAGTCGACCTAGTGATGGTG-GTGATGATGATGATGATGGTGT-3= with a C-terminal His 6 tag. TAP2 was amplified with 5=-TAGGATCCATGGCTAGGTT-GCCCGACTTGA-3= and 5=-TATGATCAGTCGACTTATTC-CTCGATTCCTTCGGGTCGA-3= containing a C-terminal C8 epitope tag (PDRPEG). Both were cloned into pFastBac1 (Invitrogen, Carlsbad, CA, USA), and Tsn, amplified via 5=-ATG-GATCCTGATCAGTCGACATGAAGTCCCTGTC TCTGCTC-CTCG-3= and 5=-TAGGATCCATAGCTAGCCTCTGCT-TTCTTCTTTGAATCCTTGCA-3=, was inserted upstream of TAP. The linkers, obtained via primer annealing, were inserted between these two. Linkers were composed of serine and glycine residues with a protease cleavage site of tobacco etch virus (TEV) in the middle. Recombinant baculoviruses were created using the Bac-to-Bac system (Invitrogen). For expression in human cells, the cassettes coding for Tsn-linker-TAP were cloned into phosphorylated internal ribosome entry site 2 (pIRES2)-enhanced green fluorescent protein (EGFP) (Clontech Laboratories Inc., Palo Alto, CA, USA). For immunofluorescence, Tsn-TAP1 and Tsn-TAP2 were cloned into the separate multiple cloning sites of pVitro-neo-mcs (InvivoGen, San Diego, CA, USA). Soluble Tsn, lacking the C-terminal 36 residues, was amplified with 5=-GAGAGAAGATCTACCATGAAGTCCCT-GTCTCTGC-3= and 5=-TCGATCGCGGCCGCTCAGTCCTCAAG GGAGGGC-3=, then cloned into pcDNA3.1(ϩ) (Invitrogen). The Tsn-TMD 0 fusion constructs and the plasmid coding for wild-type (wt) TAP1 and TAP2 have been described previously (10) .
Membrane preparation, peptide binding, and transport
Sf9 insect cells were infected with baculoviruses coding for the indicated proteins and harvested after 48 h. Cell pellets were resuspended in 50 mM Tris/HCl (pH 7.4) containing 250 mM sucrose and 1% protease inhibitor mix (Serva, Heidelberg, Germany), then opened using a glass homogenizer. After centrifugation for 10 min at 4°C and 700 g, the supernatant was collected, and membranes were pelleted at 100,000 g for 30 min at 4°C. Peptide binding was measured by incubating crude membranes in PBS with 5 mM MgCl 2 with radiolabeled R9LQK peptide for 15 min on ice. For background determination, 400-fold excess of unlabeled peptide was included. After washing, the amount of bound peptide was determined by ␥-counting. Peptide transport using fluorescently labeled peptide was conducted as described previously (8) in the absence (ϪATP) and presence (ϩATP) of 3 mM ATP. Shown is a representative of 2 experiments with 3 replicates each.
Cell lines and transfection
HeLa and HEK 293T cells were cultured in DMEM (PAA Laboratories, Colbe, Germany) supplemented with 10% fetal calf serum (FCS; Biochrom AG, Berlin, Germany). The TAP-deficient cell lines BRE und STF (29) were kept in DMEM with 10% FCS and 100 g/ml Hygromycin B (SigmaAldrich, St. Louise, MO, USA). M553 is a human Tsndeficient melanoma cell line (30, 31) (35) , mouse anti-His (Pierce Biotechnology, Rockford, IL, USA). For coimmunoprecipitation, mouse anti-His (Sigma-Aldrich) or mouse anti-C8 were used. For mock control, a mouse isotype control antibody (AbCam) was used. Immunofluorescence was performed with the following antibodies: mouse anti-TAP1 148.3 (for simultaneous detection of Tsn-TAP1 and Tsn-TAP2, 148.3 was directly labeled with DyLight488; Thermo Scientific, Rochester, NY, USA) and anti-C8. As organelle markers, rabbit anti-CAL (polyclonal IgG fraction, Sigma-Aldrich), anti-ERGIC-53 (SigmaAldrich), and anti-GM130 (Golgi; EP892Y; AbCam) were used. Fluorophore-coupled secondary antibodies were donkey anti-mouse-Alexa488 (Invitrogen), anti-mouse-Alexa633 (Invitrogen), and goat anti-rabbit-Cy3 (Dianova, Hamburg, Germany). For flow cytometric detection of MHC I, anti-HLA A/B/C (W6/32)-phycoerythrin (PE) (BioLegend, San Diego, CA, USA) was used: it specifically recognizes folded, ␤ 2 massociated, and peptide-loaded MHC I molecules.
Disulfide conjugate detection
Transiently transfected HEK 293T cells were harvested 48 h after transfection. After washing with cold PBS, cells were incubated for 5 min with 10 mM methyl methanethiosulfonate (MMTS) on ice. Cells were solubilized for 30 min on ice with TBS buffer plus 1% Triton X-100, 2 mM MMTS, and 1% benzamidine. After centrifugation at 800 g for 10 min at 4°C, SDS sample buffer with or without 400 mM ␤-mercaptoethanol was added, and samples were heated to 65°C for 10 min. After addition of 15 mM iodoacetamide and 5 min incubation at room temperature, samples were subjected to SDS-PAGE and immunoblotting. A representative result out of 3 experiments is shown.
Immunofluorescence and image processing
Immunofluorescence staining, image acquisition, and processing were performed as described (10) . For labeling with anti-TAP1 [monoclonal antibody (mAb) 148.3] conjugated to DyLight488, cells were washed and incubated with the antibody after incubation with the labeled secondary antibodies. Immunostainings are representative of Ն10 different images.
Coimmunoprecipitation
Before harvest, transiently transfected cells were treated with interferon-␥ (7 ng/ml; ϳ350 IU/ml) for 48 h to enhance endogenous TAP and MHC I levels. Coimmunoprecipitation was performed as described previously (10) . All immunoprecipitation experiments were performed Ն3 times.
Flow cytometry
Transiently transfected cells were harvested 40 h after transfection and washed once with cold FACS buffer (PBS/2% FCS). After blocking with 5% BSA in FACS buffer, cells were washed twice and incubated with anti-HLA-A/B/C (W6/ 32)-PE or the PE-coupled isotype control antibody for 15 min on ice in the dark. Cells were again washed twice and FACS analysis was performed using a FACSCalibur (BD Biosciences, San Jose, CA, USA). Data were analyzed with FlowJo software (TreeStar, Ashland, OR, USA). For evaluation, a FSC/SSC gate was drawn around the main cell population, and only GFP-positive cells were analyzed with respect to MHC I surface expression. All flow cytometry experiments were performed Ն3 times.
RESULTS
Design of symmetric and asymmetric MHC I peptideloading complexes with defined stoichiometry
Cellular pathways including MHC I antigen processing are controlled by multi-subunit complexes. Such complexes are often highly dynamic entities, which are intrinsically difficult to analyze in vivo and in vitro. To overcome these obstacles, a gene-fusion strategy has evolved as a method of choice. For example, the transient interaction between the signal recognition particle (SRP) protein Ffh and its receptor FtsY was stabilized by a glycine-serine linker to trap the Escherichia coli ribosome with SRP and its receptor (36) . Notably, the interaction between the TAP complex and the MHC I specific chaperone Tsn is very labile, and the least characterized one. For analysis of the stoichiometry within the PLC, we aimed at stabilizing this transient interaction and assembling a PLC in a symmetric and asymmetric way, in which the Tsn-MHC I subcomplex is bound either to TAP1 or TAP2. Since the short C-terminal tail of Tsn and the N termini of TAP1 and TAP2 are located in the cytosol (9, 27), we bridged Tsn to either TAP1 or TAP2 via a flexible glycine-serine linker of 18, 26, and 34 aa (Fig. 1B) . For detection and coimmunoprecipitation, Tsn-TAP1 and Tsn-TAP2 harbored a His 6 tag and a C8 tag at the C terminus, respectively. All Tsn-TAP fusion constructs could be expressed in HeLa cells, as detected by immunoblotting (Fig. 1C) . Only in the case of Tsn-TAP2, the very short linker impaired the expression of the full-length fusion protein, resulting in a degradation product of ϳ50 kDa, which corresponds to Tsn plus part of the linker. Unless indicated otherwise, the 34mer linker was chosen for all further experiments.
Tsn-TAP fusions are ER resident and recruit ERp57
Tsn possesses a double-lysine motive for Golgi-ER retrieval (37), while TAP does not contain any known ER retention or retrieval signal. TAP is predominantly localized in the ER, although some TAP activity was reported in a post-ER compartment (38 -42) . We therefore analyzed whether the fusion of Tsn alters the subcellular localization of TAP in HeLa cells (Fig. 2) . As revealed by immunofluorescence, Tsn-TAP1 and Tsn-TAP2 are retained in the ER, similar to wt TAP. Based on the ER localization of fusion constructs, we next examined correct folding and function of Tsn within the Tsn-TAP complex by specific recruitment of the ER-resident disulfide isomerase ERp57, which forms a mixed disulfide conjugate critical for MHC I loading (4, 14) . As shown in Fig. 3 , Tsn-TAP1 and Tsn-TAP2 form conjugates of 190 kDa, each consisting of TAP, Tsn, and ERp57, as detected by nonreducing SDS-PAGE and immunoblotting. Based on the large cellular pool, the majority of ERp57 is free. The ERp57-Tsn-TAP complex dissociated into Tsn-TAP (130 kDa) and free ERp57 (60 kDa) under reducing conditions, confirming the correct folding and formation of a mixed disulfide bridge between Tsn-TAP and ERp57.
Tsn-TAP fusion constructs are functional in peptide translocation and MHC I loading
We next investigated whether the linker approach impaired the function of Tsn and TAP. WT TAP and Tsn-TAP fusion constructs were expressed in insect cells, and the ER translocation of fluorescein labeled peptides was analyzed (Fig. 4A) . The transport activity was normalized to the amount of active TAP as determined by peptide binding. As a result, Tsn-TAP displayed the same peptide transport activity into the ER lumen as wt TAP, demonstrating that TAP function is not impaired by Tsn fusion. To analyze the effect of the Tsn-TAP fusion in MHC I loading and antigen processing, Tsn-TAP and wt TAP were expressed in human BRE-169 and STF-169 cells, derived from fibroblasts of patients with bare lymphocyte syndrome (type I) and deficient in TAP1 and TAP2, respectively (29) . In these TAP-negative cells, MHC I peptide loading and surface expression are significantly impaired due to the defect in one TAP subunit. As expected, transfection of the deficient TAP subunit restored MHC I surface expression. Notably, the Tsn-TAP construct enhanced MHC I 
Two Tsn binding sites of the TAP complex can be occupied simultaneously
We have recently identified the TMD 0 s of each TAP subunit as autonomous interaction scaffolds for the recruitment of Tsn (10). However, a key question remained whether these interaction domains located at each TAP subunit can be occupied simultaneously. Therefore, Tsn-TAP fusion constructs were expressed in HeLa cells. To promote heterodimer formation, the corresponding wt TAP counterpart was coexpressed. Subsequently, Tsn-TAP1 and Tsn-TAP2 were immunoprecipitated by specific antibodies directed against the C-terminal tags. In case of a simultaneous binding of 2 Tsn molecules, free endogenous Tsn should be eluted via the wt counterpart, forming a mixed heterodimeric complex. Indeed, endogenous free Tsn was coimmunoprecipitated with the mixed, asymmetric Tsn-TAP1/ TAP2 and TAP1/Tsn-TAP2 complexes, indicating that maximal 2 Tsn molecules can be recruited simultaneously in the PLC (Fig. 5) .
One Tsn molecule per PLC bound to either TAP1 or TAP2 is sufficient for MHC I loading
Since a fully assembled PLC can recruit 2 Tsn molecules, we aimed at finding out how many Tsn molecules are minimally required for efficient MHC I loading and antigen processing. Tsn-TAP1 and Tsn-TAP2 were therefore expressed alone or in combination in Tsndeficient human melanoma M553 cells, thereby creating asymmetric and symmetric PLCs with defined Tsn/ TAP ratios of 1:1 and 2:1, respectively. Peptide-MHC I complexes were monitored at the cell surface by FACS red.
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analysis. As expected, mock-transfected M553 cells exhibited very low MHC I surface levels, while transfection with wt Tsn led to a dramatic increase (Fig. 6A, left  panel) . Interestingly, Tsn Ϫ/Ϫ cells transfected either with Tsn-TAP1 or Tsn-TAP2 displayed the same MHC I surface level as cells transfected with wt Tsn. This clearly demonstrates that one Tsn molecule either bound to TAP1 or TAP2 is sufficient to mediate MHC I loading. Expression of the Tsn-TAP fusions as fulllength proteins was confirmed by immunoblotting (Fig.  6B) . Expression of wt TAP1/2 in the absence of Tsn did not change MHC I surface expression. Notably, double transfections with Tsn-TAP1 and Tsn-TAP2 lead to MHC I surface levels that exceeded those caused by wt Tsn, demonstrating that the Tsn-TAP1/2 complex is optimally preassembled for MHC I loading and that recruitment of Tsn to TAP might be the rate-limiting state (Fig. 6A, right panel) .
A proximity between Tsn and TAP is crucial for antigen processing
The mechanism by which Tsn samples the peptide repertoire on MHC I has lately been investigated (12, 13, 15, (43) (44) (45) . By binding simultaneously to TAP and MHC I, Tsn ensures a spatial proximity between the peptide supplier TAP and the peptide acceptor MHC I. Soluble Tsn is known to enhance MHC I surface expression in Tsn-deficient cells, but not to the same extent as wt Tsn (18, 20) . We therefore created additional fusion constructs, named Tsn-TMD 0 TAP1 or Tsn-TMD 0 TAP2 , in which Tsn is located in the ER membrane, but TAP binding is blocked by its tethered interaction scaffold. After expressing Tsn-TMD 0
TAP1
and Tsn-TMD 0 TAP2 in Tsn-deficient M553 cells, their interaction with PLC components was analyzed by coimmunoprecipitation using antibodies against the myc or HA tag of Tsn-TMD 0 TAP1 and Tsn-TMD 0 TAP2 , respectively. To enhance the low endogenous MHC I and TAP levels, the cells were stimulated with interferon-␥. As shown in Fig. 7A , MHC I interacts with both Tsn-TMD 0 TAP1 and Tsn-TMD 0 TAP2 , confirming the formation of peptide-loading Tsn-MHC I subcomplexes around these minimal interaction scaffolds, while endogenous TAP is excluded. Thus, we created novel PLCs, which are organized at single TMD 0 s of TAP but lacking the peptide translocation pore. Subsequently, we assessed the MHC I surface expression by flow cytometry (Fig. 7B, C) . As expected, soluble Tsn leads to an increase in MHC I surface expression, but not to the same level as wt Tsn. Strikingly, Tsn-TMD 0
or Tsn-TMD 0 TAP2 promoted MHC I presentation only to the same extent as soluble Tsn, which is significantly less than wt Tsn. Taken together, these data illustrate Only successfully transfected, GFP-positive cells were included in the analysis. Solid gray, mock transfection; dotted black, wt TAP1 and TAP2; blue, wt Tsn; green, Tsn-TAP1; red, Tsn-TAP2; solid black, Tsn-TAP1 and Tsn-TAP2. Histograms for wt Tsn, sol Tsn, and mock transfection are the same in both panels, since the data are derived from the same dataset. B) Expression of wt Tsn and the Tsn-TAP fusion proteins was confirmed by anti-Tsn immunoblotting in M55e cells used for flow cytometry. Tsn-TAP fusions were expressed at lower levels than wt Tsn. Notably, no free Tsn was released from the fusion proteins, based on intracellular cleavage. 
DISCUSSION
This work reports on the structural organization of TAP and Tsn in the PLC. To assess the effect of PLCs with defined stoichiometries, TAP and Tsn fusion constructs were created. Since structural information on the TAPTsn binding site is still missing, we screened flexible linkers of different lengths. Interestingly, Tsn-TAP2 with the short 18-aa linker was unstable, resulting in a degradation product of the size of Tsn plus the linker. This fits well with membrane topology models that suggest a very short cytosolic N terminus for TAP2 as compared to TAP1 (10) . This explains also why predication algorithms mistakenly placed the N terminus of TAP2 into the ER lumen (46) . The fact that these fusion proteins were fully functional confirms recent data, demonstrating that the N termini of both TAP subunits are located in the cytosol (10, 46) . The stabilization of the labile Tsn-TAP interaction also offers interesting options for the functional and structural analysis of the PLC.
This study provides important information regarding the dynamic assembly and disassembly of the PLC. Little is known so far about the fate of the PLC after MHC I loading has been completed. Earlier models suggested that MHC I dissociates from the PLC after loading and travels to the cell surface via the secretory pathway (47, 48) . However, evidence has emerged that the PLC or at least parts of it exit the ER and can be found in post-ER compartments (38 -42, 49) . Interestingly, the fate of the Tsn-TAP interaction after peptide loading is completely unknown. It has been proposed that Tsn escorts MHC I acting also as post-ER peptide editor (38) . Our data demonstrate that MHC I loading and surface expression works with the same efficiency independent of whether Tsn is free or tethered to TAP in the ER. This suggests that the dissociation of Tsn and TAP is not an obligatory event in the cycle of MHC I loading and release. It also indicates that MHC I molecules can assemble directly with fixed ERp57-Tsn-TAP complexes without the need for a preassembly of a Tsn/MHC I complex.
It has been previously shown that the unique N-terminal extension of each TAP subunit, named TMD 0 TAP1/2 , harbors a single Tsn-binding site (10) . Here, we provide direct evidence that indeed both of these interaction sites can be occupied at the same time, leading to the PLC with maximal activity (Fig. 6 ). This ends up in a Tsn/TAP ratio of 2:1 within a optimally assembled PLC, which is in perfect agreement with the stoichiometry found for a rat TAP complex (28) and a very recent study using a different approach (50) . The finding that the Tsn:MHC I ratio varies between 2:1 and 2:2 complements our results, especially since we found PLCs with two bound Tsn molecules to be more efficient in MHC I surface presentation than wt PLCs. Since the X-ray structure shows that Tsn and ERp57 form a 1:1 complex (5), we concluded that the PLCs in mammals are composed of 2x Tsn-ERp57/MHC I assembled around one TAP complex.
We also assessed the minimal number of Tsn molecules in the PLC required for efficient peptide loading. Strikingly, one Tsn molecule per PLC bound either to TAP1 or TAP2 is sufficient to mediate MHC I loading (Fig. 6) . Taking the proposed mechanism into account by which Tsn edits the peptide repertoire in MHC I (13, 44) , it seems plausible that one Tsn molecule can catalyze the loading of high-affinity peptide onto MHC I. It also supports a recent finding suggesting that at each time point only one MHC I assembly platform is engaged in peptide loading (28) . This gives rise to the following interesting question: why this obvious redundancy of having two Tsn molecules in a complex where one is sufficient? Answers may come from future studies systematically addressing the Tsn-TAP interaction and the effect in antigen processing in different species. For example, avians comprising an asymmetric TAP complex with only one TMD 0 interaction scaffold at TAP2 are likely to recruit only one Tsn molecule into their PLCs. For the human PLC, we found equal promotion of MHC I surface presentation no matter whether the single Tsn molecule was bound to TAP1 or TAP2, suggesting a functional equivalence of both Tsn binding sites despite their pronounced differences in sequence. The finding that two stably preassembled Tsn molecules are more efficient in MHC I loading than wt PLCs indicate that the excess of endogenous Tsn, which is not associated with TAP, but interacting with MHC I, competes for optimal loading of MHC I molecules within the PLC. Thus, a large fraction of PLCs might be suboptimally equipped with Tsn and / or MHC I and a second docking platform could therefore promote peptide loading of a broader range of Tsndependent MHC alleles.
Several studies reported on the importance of the transmembrane helix of Tsn for peptide editing, but all (19 -21, 51) . So it remained unclear whether the spatial proximity alone plays a role or the interaction with TMD 0 maintains Tsn in a conformation that enables peptide editing. By using Tsn-TMD 0 fusion proteins, we captured Tsn bound to its interaction domain. In this case, physical contact and proximity (5 nm) between the peptide transport pore and the peptide binding pocket of MHC I was abolished. In contrast to wt Tsn, Tsn-TMD 0 TAP1 or Tsn-TMD 0 TAP2 enhanced MHC I surface presentation only to a limited level similar to soluble Tsn, suggesting that indeed the proximity between MHC I and TAP is crucial for peptide loading. An obvious test for this hypothesis would be the analysis of MHC I peptide loading in the opposed case, meaning the formation of PLCs in which the spatial proximity between the peptide translocation pathway is granted but the native interaction between TAP and Tsn is disturbed. For this, we created an additional set of constructs by fusing Tsn directly to coreTAP1 or coreTAP2, thereby omitting the Tsn-binding domain TMD 0 . However, when expressed in Tsn-deficient cells, these fusion proteins were unstable, leading to a formation of free Tsn and thus making the analysis obsolete. However, the reason for the requirement of proximity between peptide translocation and loading remains unclear. By permanently shuffling antigen-derived peptide into the ER, an increased local concentration of peptides is generated within the PLC. This local peptide pool could promote peptide editing and formation of kinetically stable peptide-MHC I complexes. This view is supported by the finding that in TAP1/2 negative T2 cells, MHC I molecules remain in the ER for extended periods of time and are rapidly released after artificial peptide supplementation (48) .
Altogether, our data lead to a model in which a fully assembled human PLC comprises two Tsn molecules, one attached to the TMD 0 of each TAP subunit (Fig. 8A) . However, a PLC comprising only one Tsn molecule is sufficient for MHC I loading. As autonomous assembly scaffold, the TMD 0 s provide the necessary spatial proximity of peptide supply by coreTAP and peptide consumption by MHC I (Fig. 8B) . After loading high-affinity peptides, MHC I can dissociate from the ERp57-Tsn-TAP complex.
